The Swiss drugmaker conducted two identically designed studies, each involving about 1,000 participants, who were examined by doctors over two years. In each study, volunteers were randomly assigned to receive gantirumab and some to receive gantirumab medicine imaginary.
The company said, in a statement, that the drug was associated with a relative decrease in deterioration symptoms By about 8 percent in one of the two studies and 6 percent in the other study when comparing those who received the drug and those who were given a placebo, but she added that these results are not statistically significant.
Roche shares fell 4.4 percent to their lowest in about seven weeks.
My company’s shares went up "Biogen" And"Eli Lilly" Americas Industry pharmaceutical Which are developing competing treatments for Alzheimer’s disease, up 3.8 percent and 2.3 percent, respectively, in pre-market trading.
In September, Biogen scored a surprising success on an experimental Alzheimer’s disease drug it had developed with Essay.
The two companies said, at the time, that their experimental drug "Licanimab" It slowed the progression of Alzheimer’s disease by 27 percent compared with a placebo in a large trial of patients in the early stages of onset of symptoms.
“>
Roche said, in a statement today, Monday, that the two studies, which were conducted together, did not reach the desired goal of proving that the drug “Gantirumab” can preserve abilities such as memory, problem-solving, orientation and personal care in patients in the early stages of disease. Alzheimer’s.
The Swiss drugmaker conducted two identically designed studies, each involving about 1,000 participants, who were examined by doctors over two years. In each study, volunteers were randomly assigned to receive gantirumab and some to receive gantirumab medicine imaginary.
The company said, in a statement, that the drug was associated with a relative decrease in deterioration symptoms By about 8 percent in one of the two studies and 6 percent in the other study when comparing those who received the drug and those who were given a placebo, but she added that these results are not statistically significant.
Roche shares fell 4.4 percent to their lowest in about seven weeks.
The shares of the American companies “Biogen” and “Eli Lilly” rose pharmaceutical Which are developing competing treatments for Alzheimer’s disease, up 3.8 percent and 2.3 percent, respectively, in pre-market trading.
In September, Biogen scored a surprising success on an experimental Alzheimer’s disease drug it had developed with Essay.
At the time, the companies said their experimental drug, licanimab, slowed the progression of Alzheimer’s disease by 27 percent compared to a placebo in a large trial in patients in the early stages of onset of symptoms.